Sinopia Biosciences Awarded $1.5 million NHLBI Phase II SBIR

Sinopia Biosciences received a Phase II Small Business Innovation Research (SBIR) Grant from the National Heart, Lung, and Blood Institute (NHLBI) branch of the National Institutes of Health (NIH). Titled "Improving red blood cell transfusion through systems biology", the award for approximately $1.5 million will support the experimental deployment of Sinopia's platform for transfusion medicine. In Phase I, Sinopia’s systems biology platform discovered a non-linear decay process for red blood cell storage and how the cell’s metabolism changes over time. The detected changes were shown to have potential clinical relevance. This Phase II grant focuses on testing novel additives to combat the metabolic changes in order to better preserve red blood cells for transfusion. The multi-center project will involve key collaborations with the San Diego Blood Bank and blood metabolomics experts at the University of Colorado Denver.